Stockreport

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF ResQ215B builds on a Phase 1 study that demonstrated that CAR-NK cell therapy plus rituximab administered without chemotherapy or ANKTIVA in iNHL, including Waldenström [Read more]